Celldex Therapeutics

CLDXNasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$3.274 B

$41.71 +0.36%

Close of 7 Aug 2026

Revenue

$1.54M

#3464 by revenue

Earnings

-$258.8M

Loss-making

Shares outstanding

78,529,532

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances — ranked by market cap

All 19 →

#2LantheusLNTH$6.57B
#3Oruka TherapeuticsORKA$5.96B
#4Celldex TherapeuticsCLDX$3.27B
#5NeogenNEOG$2.50B
#6Intellia TherapeuticsNTLA$1.67B

Where these numbers come from

Share counts and financials for Celldex Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.